SK-LMS-1 Cells

CAD$759.00*

Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 10⁶ cells for adherent lines or 5 × 10⁶ cells for suspension lines (refer to the batch CoA for details).

Prices excl. taxes plus shipping costs

cryovial

Product number: 300125

Safety data sheet

Product sheet

Certificate of Analysis (CoA)

Description	SK-LMS-1 is a human leiomyosarcoma cell line that has been widely used for cancer research, particularly for studies investigating therapeutic agents targeting soft tissue sarcomas. Leiomyosarcoma is a type of malignant tumor that arises from smooth muscle tissues, and the SK-LMS-1 cell line models this disease effectively in vitro. These cells express the c-Met proto-oncogene, which plays a critical role in tumorigenesis, proliferation, and metastasis in many cancers, including leiomyosarcoma. The aberrant expression of c-Met in SK-LMS-1 makes it a valuable model for studying c-Met-targeted therapies. One significant study involved the identification of a Met-binding peptide, Met-pep1, through phage display library screening. This peptide demonstrated specificity for the Met receptor and was capable of competing with hepatocyte growth factor (HGF) for receptor binding, inhibiting tumor cell proliferation. SK-LMS-1 cells treated with Met-pep1 showed decreased proliferation, suggesting that targeting c-Met with this peptide could have therapeutic potential. The internalization of the peptide by SK-LMS-1 cells after binding to c-Met further supports its potential as a diagnostic or therapeutic agent, particularly in nuclear imaging studies where tumor-associated activity was successfully visualized in vivo using SK-LMS-1 xenografts. Additionally, SK-LMS-1 cells have been used to explore the effects of natural compounds such as Flavokawain B (FKB), a chalcone derived from the kava plant. FKB was found to induce G2/M cell cycle arrest and robust apoptosis in SK-LMS-1 cells, mediated by the upregulation of pro-apoptotic proteins like DR5, Bim, and Puma, and downregulation of the anti-apoptotic protein survivin. The combination of FKB with chemotherapeutic agents such as docetaxel and gemcitabine exhibited a synergistic effect, further inhibiting the growth of SK-LMS-1 cells.
Organism	Human
Tissue	Vulvar
Disease	Leiomyosarcoma
Synonyms	SKLMS-1, SKLMS1

Age	43 years
Gender	Female
Ethnicity	Caucasian
Morphology	Fibroblast-like
Growth properties	Adherent

Citation	SK-LMS-1 (Cytion catalog number 300125)
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_0628

Antigen expression	Blood Type O, Rh+
Isoenzymes	Me-2, 2, PGM3, 1-2, PGM1, 1-2, ES-D, 1, AK-1, 1, GLO-1, 1-2, G6PD, B, Phenotype Frequency Product: 0.0027
Tumorigenic	Yes, in nude mice. Forms leiomyosarcoma
Karyotype	(P12) hypotriploid to hypertriploid (+A2, +A3, +C, +D, +E, +F, +G, -A) with abnormalities including dicentrics, acrocentric fragments, breaks, secondary constrictions, minutes and large submetacentric markers

Culture Medium	DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
Supplements	Supplement the medium with 10% FBS
Dissociation Reagent	Accutase
Subculturing	Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
Fluid renewal	2 to 3 times per week
Freeze medium	As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
Thawing and Culturing Cells	Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.
Incubation Atmosphere	37°C, 5% CO₂, humidified atmosphere.
Shipping Conditions	Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.
Storage Conditions	For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Sterility	Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Lot Number	Certificate Type	Date	Catalog Number
300125-719	Certificate of Analysis	23. May. 2025	300125

SK-LMS-1 Cells

General information

Characteristics

Regulatory Data

Biomolecular Data

Handling

Quality Control & Molecular Analysis

Certificate of Analysis (CoA)

Organism	Human
Tissue	Breast, mammary gland
Disease	Invasive ductal carcinoma

Organism	Human
Tissue	Lung
Disease	Adenocarcinoma (grade III)